Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a single protein explain Asthma's many faces?

NCT ID NCT07786870

Knowledge-focused Sponsor: Medical University of Warsaw Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This study looks at a protein called TSLP, which is involved in airway inflammation, and its two forms (short and long) in people with different types of asthma. Researchers will measure TSLP levels in blood and nasal cells from 70 adults with asthma and compare them to healthy controls. The goal is to see if TSLP patterns relate to asthma severity, control, and specific features like allergy or inflammation type. This could help tailor future asthma treatments to individual patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help identify which asthma patients might benefit most from TSLP-targeting therapies, potentially leading to more personalized treatment approaches.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The findings may not apply to all asthma patients, and the results depend on accurate measurement of TSLP levels in samples.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with severe asthma, with different asthma phenotypes (allergic and non-allergic asthma; eosinophilic, neutrophilic, and paucigranulocytic asthma; early-onset and late-onset asthma; obesity-associated asthma; cough-variant asthma).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

1. Inclusion criteria * age \> 18 years, without the upper age limit, * asthma (diagnosis in accordance with the GINA 2023 guidelines), 2. Exclusion criteria * other respiratory diseases (e.g., chronic obstructive pulmonary disease \[COPD\]); * active cigarette smoking or a smoking history of \>10 pack-years; * active malignancy; * active pulmonary tuberculosis or active respiratory tract infection; * use of antibiotics within 4 weeks prior to study enrollment; * current long-term home oxygen therapy (\>15 hours per day); * current treatment with monoclonal antibody therapies (e.g., omalizumab, mepolizumab, reslizumab, dupilumab, tezepelumab, or other biologics); * pregnancy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma atopic are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic asthma asthma chronic asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma atopic Asthma severe persistent uncontrolled

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, Warsaw, Poland,

    RECRUITING

    Warsaw, Warsaw, 02-097, Poland